independence blue cross glp 1 GLP-1 Drugs Could Raise Employer Health Premiums Starting in the new year,

In the US, it depends on Medicare and Medicaid coverage , if the Trump administration continues Biden's legacy of including these drugs and considers obesity a chronic disease, this could mean an additional cost of up to $35 billion by 2034, according to the Congressional Budget Office

Average weight loss in 64 week medical study XYOSTED Auto-Injector Testosterone Cypionate Testosterone Topical Gel Dr

Recognized as having "zero sugar", allulose is an excellent way to sweeten food or beverages

With xerostomia, the salivary glands do not produce enough saliva, leading to oral dryness and potential oral health problems

Global Glp 1 Receptor Agonists Obesity Drugs Market Market Size in USD Billion GLP-1 Receptor Agonists Obesity Drugs Market Size The global GLP-1 receptor agonists obesity drugs market size was valued at USD 9.96 billion in 2024 and is expected to reach USD 33.12 billion by 2032 , at a CAGR of 16.21% during the forecast period The market growth is primarily driven by the increasing need for secure, transparent, and tamper-proof systems to manage sensitive healthcare data, billing processes, and patient records across diverse stakeholders In addition, the rising adoption of blockchain technology by healthcare providers, insurers, and pharmaceutical companies to streamline operations, enhance data integrity, and mitigate fraud is propelling market expansion

Although these studies cannot prove causation, the consistent findings across large populations, systems, and countries provide compelling early evidence that GLP-1 medications could reduce alcohol and drug use and could play an important role in SUD treatment